Voyager Therapeutics Inc. Common Stock (VYGR)

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV)…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

141

Website

www.voyagertherapeutics.com/

Fundamentals

1-day range

$3.36$3.56

Market cap

$181.26M

P/E (trailing)

—

P/E (forward)

-2.77

EPS (trailing)

$-1.81

Dividend yield

—

Beta

1.26

Avg. volume

599.9K

Forecasts

9 analyst ratings

Voyager Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54
• TARA

  Protara Therapeutics Inc. Common Stock

  $3.82

  ▼ 4.26%
  Market cap $223.13MP/E —
  $3.02$7.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
  benzinga · 8/10/2026

Institutional Ownership

March 31, 2026

Total shares held

32.43M

Total value held

$123.36M

Institutional holders

130